Update Mammakarzinom 2024 Teil 3 – Patientinnen mit fortgeschrittenen Stadien des Mammakarzinoms

Zusammenfassung

Mit den CDK4/6-Inhibitoren, den neuen PI3K/AKT-Kinase-Inhibitoren, den selektiven Östrogenrezeptor-Degradern (SERDs), den Antikörper-Wirkstoff-Konjugaten, den Immuntherapien und den PARP-Inhibitoren wurde die Therapielandschaft von Patientinnen mit fortgeschrittenem Mammakarzinom in den letzten Jahren deutlich zum Positiven verändert. CDK4/6-Inhibitoren, Trastuzumab-Deruxtecan und Sacituzumab-Govitecan haben zudem alle einen signifikanten Gesamtüberlebensvorteil gegenüber konventioneller Chemotherapie nachgewiesen. Weitere Substanzen zeigen ebenfalls vielversprechende Daten, die hoffen lassen, dass in naher Zukunft weitere Analysen mit einem Gesamtüberlebensvorteil vorliegen. Die Geschwindigkeit der Studiendurchführung hat deutlich zugenommen, sodass die Kongresse zusammen mit den Fachzeitschriften eine stetige Quelle neuer Informationen bieten. Diese Übersichtsarbeit fasst die jüngsten Veröffentlichungen und Kongresspräsentationen über die Behandlung von Patientinnen mit fortgeschrittenen Stadien einer Mammakarzinomerkrankung zusammen.

Schlüsselwörter

Mammakarzinom - Mammakarzinom im fortgeschrittenen Stadium - klinische Studien - Prognose

Publikationsverlauf

Eingereicht: 20. November 2024

Angenommen nach Revision: 07. Dezember 2024

Artikel online veröffentlicht:
15. Mai 2025

• References/Literatur

• 1 Robson M, Im S-A, Senkus E. et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 2017; 377: 523-533
• 2 Litton JK, Rugo HS, Ettl J. et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med 2018; 379: 753-763
• 3 Turner NC, Telli ML, Rugo HS. et al. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clin Cancer Res 2019; 25: 2717-2724
• 4 Robson ME, Tung N, Conte P. et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physicianʼs choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 2019; 30: 558-566
• 5 Fasching PA, Hu C, Hart SN. et al. Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer. NPJ Breast Cancer 2024; 10: 57
• 6 Ettl J, Quek RGW, Lee KH. et al. Quality of life with talazoparib versus physicianʼs choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol 2018; 29: 1939-1947
• 7 Thill M, Janni W, Albert US. et al. Arbeitsgemeinschaft Gynakologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024. Breast Care (Basel) 2024; 19: 183-191
• 8 Tung NM, Robson ME, Ventz S. et al. TBCRC048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded). J Clin Oncol 2020; 38: 1002
• 9 Tung NM, Robson ME, Nanda R. et al. TBCRC048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2. J Clin Oncol 2024; 42: 1021-1021
• 10 Fasching PA, Yadav S, Hu C. et al. Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer-Association With Patient and Disease Characteristics and Effect on Prognosis. J Clin Oncol 2021; 39: 1619-1630
• 11 Hortobagyi GN, Stemmer SM, Burris HA. et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med 2022; 386: 942-950
• 12 Slamon DJ, Neven P, Chia S. et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med 2020; 382: 514-524
• 13 Im SA, Lu YS, Bardia A. et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med 2019; 381: 307-316
• 14 Goetz MP, Toi M, Huober J. et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol 2024; 35: 718-727
• 15 Engler T, Fasching PA, Luftner D. et al. Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT. Geburtshilfe Frauenheilkd 2022; 82: 1055-1067
• 16 Braun M, Stoetzer O, Salat C. et al. Current therapy landscape of advanced HER2 negative breast cancer in pateints in a network of office based internistic oncologists and gynecologic oncologists in Germany. Deutscher Krebskongress 2022; Abstract 306.
• 17 Hartkopf A. Therapy landscapes and molecular markers, the German PRAEGNANT registry. ESMO Breast Cancer Conference 2022. Zugriff am 10. November 2022 unter: https://oncologypro.esmo.org/meeting-resources/esmo-breast-cancer-congress/therapy-landscapes-and-molecular-markers-the-german-praegnant-registry
• 18 Bidard FC, Kaklamani VG, Neven P. et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol 2022; 40: 3246-3256
• 19 Turner NC, Oliveira M, Howell SJ. et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2023; 388: 2058-2070
• 20 Andre F, Ciruelos E, Rubovszky G. et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2019; 380: 1929-1940
• 21 Untch M, Ditsch N, Fasching PA. et al. Discussion of ABC7 Consensus and German Recommendations. Geburtshilfe Frauenheilkd 2024; 84: 431-442
• 22 Würstlein R, Kolberg HC, Hartkopf AD. et al. Update Breast Cancer 2024 Part 1 – Expert Opinion on Advanced Breast Cancer. Geburtshilfe Frauenheilkd 2024; 84: 529-540
• 23 Cardoso F, Paluch-Shimon S, Schumacher-Wulf E. et al. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast 2024; 76: 103756
• 24 Kalinsky K, Bianchini G, Hamilton EP. et al. Abemaciclib plus fulvestrant vs. fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial. J Clin Oncol 2024; 42: LBA1001
• 25 Kalinsky K, Accordino MK, Chiuzan C. et al. Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial. J Clin Oncol 2023; 41: 4004-4013
• 26 Albanell J, Pérez-García JM, Gil-Gil M. et al. Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial. Clin Cancer Res 2023; 29: 67-80
• 27 Mayer EL, Ren Y, Wagle N. et al. PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. J Clin Oncol 2024; 42: 2050-2060
• 28 Schneeweiss A, Brucker SY, Huebner H. et al. CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs. Geburtshilfe Frauenheilkd 2024; 84: 443-458
• 29 Turner NC, Ro J, Andre F. et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med 2015; 373: 209-219
• 30 OʼLeary B, Cutts RJ, Liu Y. et al. The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. Cancer Discov 2018; 8: 1390-1403
• 31 Tolaney SM, Toi M, Neven P. et al. Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant. Clin Cancer Res 2022; 28: 1500-1506
• 32 Andre F, Su F, Solovieff N. et al. Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials. J Clin Oncol 2020; 38: 1009
• 33 Jhaveri K, Im S-A, Saura C. et al. Inavolisib or placebo in c,ombination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III INAVO120 primary analysis. San Antonio Breast Cancer Symposium; San Antonio, TX: December 5 – 8, 2024; Abstract GS3-13 2023.
• 34 Juric D, Kalinsky K, Turner NC. et al. First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses. J Clin Oncol 2024; 42: 1003
• 35 Cortes J, Kim SB, Chung WP. et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med 2022; 386: 1143-1154
• 36 Modi S, Saura C, Yamashita T. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med 2020; 382: 610-621
• 37 Modi S, Jacot W, Yamashita T. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 2022; 387: 9-20
• 38 Curigliano G, Hu X, Dent RA. et al. Trastuzumab deruxtecan (T-DXd) vs. physicianʼs choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). J Clin Oncol 2024; 42: 1025
• 39 Venetis K, Crimini E, Sajjadi E. et al. HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. Front Mol Biosci 2022; 9: 834651
• 40 Fitzgibbons PL, Connolly JL. College of American Pathologists (CAP). Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. 2021. Accessed August 15, 2024 at: https://documents.cap.org/documents/Breast.Bmk_1.5.0.1.REL_CAPCP_R.pdf
• 41 Meric-Bernstam F, Makker V, Oaknin A. et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol 2024; 42: 47-58
• 42 Li BT, Meric-Bernstam F, Bardia A. et al. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study. Lancet Oncol 2024; 25: 707-719
• 43 Giordano A, Awan AAA, Bruce JY. et al. Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202. J Clin Oncol 2024; 42: 1005
• 44 Schmid P, Wysocki PJ, Ma CX. et al. 379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1 L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study. Ann Oncol 2023; 34: S337
• 45 Garrido-Castro AC, Kim SE, Desrosiers J. et al. SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer. J Clin Oncol 2024; 42: LBA1004
• 46 Andre F, Hamilton EP, Loi S. et al. Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07). J Clin Oncol 2021; 39: TPS1096
• 47 Swain SM, Baselga J, Kim SB. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015; 372: 724-734
• 48 Baselga J, Cortes J, Kim SB. et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119
• 49 Thill M, Kolberg-Liedtke C, Albert US. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023. Breast Care (Basel) 2023; 18: 306-315
• 50 Swain SM, Miles D, Kim SB. et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 2020; 21: 519-530
• 51 Tolaney SM, Barroso-Sousa R, Jiang Z. et al. 328 TiP Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs. a taxane, trastuzumab and pertuzumab in first-line (1 L), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09. Ann Oncol 2021; 32: S507-S508
• 52 Andre F, Hamilton EP, Loi S. et al. DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC. J Clin Oncol 2024; 42: 1009
• 53 Muller V, Hein A, Hartkopf AD. et al. Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics – A retrospective analysis of a real world registry. Eur J Cancer 2022; 172: 13-21
• 54 Rohatgi A. WebPlotDigitizer Version: 4.6. Accessed September 01, 2022 at: https://automeris.io/WebPlotDigitizer
• 55 Muller V, Nabieva N, Haberle L. et al. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. Breast 2018; 37: 154-160
• 56 Bardia A, Jhaveri K, Im SA. et al. LBA11 Datopotamab deruxtecan (Dato-DXd) vs. chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial. Ann Oncol 2023; 34: S1264-S1265
• 57 Pernas S, Im S-A, Hattori M. et al. Datopotamab deruxtecan (Dato-DXd) vs. chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study. J Clin Oncol 2024; 42: 1006
• 58 Xu B, Yin Y, Fan Y. et al. Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study. J Clin Oncol 2024; 42: 104